ReviewCurrent hypertension reports2010
Genetic testing for pheochromocytoma.
Review in Current hypertension reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Management of carotid body tumors: a retrospective multicenter study and case series.International journal of surgery case reports · 2026Article
- Pheochromocytoma Presenting With Paroxysmal Hypertensive Crises in a Previously Healthy Woman: A Case Report.Cureus · 2026Article
- Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and Paragangliomas.International journal of molecular sciences · 2024Review
- Pheochromocytoma: Secondary Hypertension in Pregnancy.JACC. Case reports · 2024Article
- Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report.BMC urology · 2023Article
- Article
- Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma.Endocrine oncology (Bristol, England) · 2023Article
- A 15-year-old girl with a parotid mass and hypertension: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Clinical, Biochemical, Tumoural and Mutation Profile of VHL- and MEN2A-Associated Pheochromocytoma: A Comparative Study.World journal of surgery · 2022Article
- Neurological Complications of Endocrine Emergencies.Current neurology and neuroscience reports · 2021Review
- AQP2 as a diagnostic immunohistochemical marker for pheochromocytoma and/or paraganglioma.Gland surgery · 2020Article
- Clinical and Biochemical Features of Pheochromocytoma Characteristic of Von Hippel-Lindau Syndrome.World journal of surgery · 2020Article
- Article
- Clinical, Diagnostic, and Treatment Characteristics ofFrontiers in oncology · 2019Article
- Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.Iranian journal of pathology · 2017Review
- Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty.Journal of pediatric endocrinology & metabolism : JPEM · 2014Article
- Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma.PloS one · 2014Article
- Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma.Endocrine connections · 2013Article
- An update on the genetics of pheochromocytoma.Journal of human hypertension · 2013Review
- Pheochromocytoma: implications in tumorigenesis and the actual management.Minerva endocrinologica · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare, catecholamine-producing tumors that are usually sporadic. However, about 30% of these tumors have been identified as being of inherited origin. To date, nine genes have been confirmed as participating in PHEO or PGL tumorigenesis. Germline mutations were found in 100% of syndromic cases and in about 90% of patients with positive familial history. In nonsyndromic patients with apparently sporadic tumors, genetic mutations have been found in up to 27%, and genetic testing is now recommended for all patients with PHEOs and PGLs. Patients with syndromic lesions, a positive family history, or both should be tested for the appertaining gene. Recent discoveries have shown that the order of tested genes in nonsyndromic, nonfamilial cases can be based on histologic evaluation, location, and the biochemical phenotype of PHEOs and PGLs--the "rule of three." Identification of a gene mutation may lead to early diagnosis and treatment, regular surveillance, and a better prognosis for patients and their relatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.